Literature DB >> 3092670

von Willebrand's disease and pregnancy: management during delivery and outcome of offspring.

J R Chediak, G M Alban, B Maxey.   

Abstract

Six patients having different subtypes of von Willebrand's disease were followed up during eight complete pregnancies. Two additional pregnancies terminated in spontaneous abortions. Five pregnancies ended in cesarean section either because of obstetric problems (three) or electively (two) to avoid infant bleeding. Three deliveries were complicated by vaginal bleeding attributed to von Willebrand's disease, while bleeding during two deliveries had clear obstetric causes. Only two deliveries were associated with no bleeding complications. Five newborn babies were found to have von Willebrand's disease. One of them was born with a head hematoma. Management, which included cryoprecipitate and desmopressin (Stimate), is discussed. It is important to manage each case individually since obstetric parameters and severity of bleeding disorder must be known before treatment is planned.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3092670     DOI: 10.1016/0002-9378(86)90290-5

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  4 in total

1.  Haemorrhagic disorders in pregnancy.

Authors:  J Jip
Journal:  J Clin Pathol       Date:  1994-06       Impact factor: 3.411

2.  Treatment of patients with von Willebrand disease.

Authors:  Emma Tuohy; Emma Litt; Raza Alikhan
Journal:  J Blood Med       Date:  2011-04-20

3.  Desmopressin acetate (DDAVP) for preventing and treating acute bleeds during pregnancy in women with congenital bleeding disorders.

Authors:  Laxminarayan Karanth; Ankur Barua; Sachchithanantham Kanagasabai; N Sreekumaran Nair
Journal:  Cochrane Database Syst Rev       Date:  2019-02-13

4.  Postpartum Hemorrhage in Women with Von Willebrand Disease - A Retrospective Observational Study.

Authors:  Igor Govorov; Signe Löfgren; Roza Chaireti; Margareta Holmström; Katarina Bremme; Miriam Mints
Journal:  PLoS One       Date:  2016-10-25       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.